ReviewBreast cancer (Dove Medical Press)2021
An Update on the Molecular Pathology of Metaplastic Breast Cancer.
Review in Breast cancer (Dove Medical Press), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Upregulation of Caveolin-1 in breast cancer and its potential value in distinguishing TNBC from non-TNBC: an immunohistochemical study.Frontiers in oncology · 2026Article
- Natural and induced epithelial-mesenchymal transition results in epigenetic silencing of HER2 overexpression.Journal of mammary gland biology and neoplasia · 2025Article
- Clinicopathological characteristics, treatments and oncological outcomes in metaplastic breast cancer: a Brazilian multicenter analysis.Frontiers in oncology · 2025Article
- NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression.Nature communications · 2024Article
- Breast Conservation Therapy for Primary Squamous Cell Carcinoma of the Breast in an Elderly Woman: A Case Report.Cureus · 2024Article
- Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience.Oncology letters · 2024Article
- Article
- Significance of Estrogen/Progesterone Receptor Expression in Metaplastic Breast Carcinoma.Disease markers · 2024Article
- A Single-Center 18-Year Series of 73 Cases of Metaplastic Carcinoma of the Breast.The breast journal · 2024Article
- SDC4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer risk.Journal of cancer research and clinical oncology · 2023Article
- Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.Histopathology · 2023Review
- Presentation and treatment of aggressive, Triple-Negative carcinosarcoma of the breast.Clinical case reports · 2022Article
- Case Report: Analysis of Plasma Extracellular Vesicles in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metaplastic breast cancer (MpBC) is a fascinating morphologic sub-type of breast cancer, characterised by intra-tumoural heterogeneity. By definition, these tumors show regions of metaplasia that can present as spindle, squamous, chondroid or even osseous differentiation. MpBC are typically triple-negative, and are therefore not targetable with hormone therapy or anti-HER2 therapies, leaving only chemotherapeutics for management. MpBC are known for their aggressive course and poor response to chemotherapy. We review herein the pathology and molecular landscape of MpBC and discuss opportunities for targetted therapies as well as immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.